Exchange: OTC·Updated 09:30 AM EDT

About

Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The firm uses its proprietary technology platform, ATLAS, to identify clinically relevant antigens of T cells based on actual human immune responses. Its product candidates include GEN-011, an investigational adoptive T cell therapy and GEN-009, a neoantigen cancer vaccine. The company was founded by Robert Paull and Kevin J. Bitterman on August 16, 2006 and is headquartered in Cambridge, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
N/A

Frequently Asked Questions

What is Market Cap of Genocea Biosciences Inc?
What is the 52-week high for Genocea Biosciences Inc?

Advertisement|Remove ads.